Published in Trends Cancer on February 01, 2016
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev (2017) 0.80
Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment. Oncoimmunology (2016) 0.78
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
CD73 is expressed by inflammatory Th17 cells in experimental autoimmune encephalomyelitis but does not limit differentiation or pathogenesis. PLoS One (2017) 0.75
Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73. BMC Cancer (2017) 0.75
Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions. J Transl Med (2016) 0.75
CD73s protection of epithelial integrity: Thinking beyond the barrier. Tissue Barriers (2016) 0.75
Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review. Oncotarget (2017) 0.75
Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
A perspective on cancer cell metastasis. Science (2011) 13.31
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res (2010) 4.15
Purinergic signaling during inflammation. N Engl J Med (2012) 4.08
Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 4.05
Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta (2008) 3.51
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
5'-Nucleotidase: molecular structure and functional aspects. Biochem J (1992) 3.08
Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology (2008) 2.99
Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal (2006) 2.98
Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol (2012) 2.94
The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 2.87
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol (1996) 2.55
Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J (2000) 2.53
mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 2.38
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 2.05
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol (2005) 1.98
Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol (2011) 1.90
The role of tumor lymphangiogenesis in metastatic spread. FASEB J (2002) 1.84
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity (2012) 1.82
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest (2011) 1.82
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol (2012) 1.81
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77
Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol (2011) 1.67
Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 1.66
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
'Cancer associated fibroblasts'--more than meets the eye. Trends Mol Med (2013) 1.52
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol (2011) 1.51
Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol (2011) 1.48
Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol (2007) 1.47
Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. Eur J Immunol (2014) 1.43
Dendritic cells in the cancer microenvironment. J Cancer (2012) 1.40
Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J (2011) 1.38
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med (1995) 1.37
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32
Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells. J Immunol (2011) 1.32
RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis (2007) 1.29
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest (2012) 1.27
A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signal (2007) 1.26
CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J Immunol (2000) 1.19
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (2011) 1.19
Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med (2011) 1.18
Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Crit Rev Biochem Mol Biol (2014) 1.18
Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ (2014) 1.18
Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov (2014) 1.17
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov (2014) 1.17
Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis (2014) 1.15
Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol (2013) 1.14
Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res (2006) 1.13
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol (2013) 1.08
CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol (2013) 1.08
The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem (2008) 1.08
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol (2014) 1.08
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology (2013) 1.07
Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids (2006) 1.07
Differential ectonucleotidase expression in human bladder cancer cell lines. Urol Oncol (2009) 1.06
Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood (2011) 1.06
CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol (2012) 1.06
Ecto-5'-nucleotidase: Structure function relationships. Purinergic Signal (2006) 1.05
Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol (2011) 1.04
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. World J Gastroenterol (2013) 1.03
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 1.01
CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function. Eur J Immunol (2013) 1.01
The roles of CD73 in cancer. Biomed Res Int (2014) 1.01
Viral vector-based therapeutic cancer vaccines. Cancer J (2011) 1.00
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol (2012) 1.00
Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer (2013) 1.00
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancer Res (2015) 1.00
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
The tumor microenvironment. Surg Oncol (2011) 0.99
The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling. Inflammation (2013) 0.99